60-day Federal Register Notice

14000

Federal Register / Vol. 82, No. 50 / Thursday, March 16, 2017 / Notices

The Commission will use the
information collected to meet its
statutory requirement under the WARN
Act to accept licensees’ election filings
and to establish an effective CMAS that
will provide the public with effective
mobile alerts in a manner that imposes
minimal regulatory burdens on affected
entities.

to Mr. Robert E. Feldman, Executive
Secretary of the Corporation, at 202–
898–7043.
Dated: March 13, 2017.
Federal Deposit Insurance Corporation.
Robert E. Feldman,
Executive Secretary.
[FR Doc. 2017–05352 Filed 3–14–17; 11:15 am]
BILLING CODE P

Federal Communications Commission.
Marlene H. Dortch,
Secretary, Office of the Secretary.

FEDERAL ELECTION COMMISSION

[FR Doc. 2017–05184 Filed 3–15–17; 8:45 am]

Sunshine Act Meeting

BILLING CODE 6712–01–P

Federal Election Commission
Tuesday, March 21,
2017 at 10:00 a.m. and its continuation
at the conclusion of the open meeting
on March 23, 2017.
PLACE: 999 E Street, NW., Washington,
DC.
STATUS: This meeting will be closed to
the public.
ITEMS TO BE DISCUSSED: Compliance
matters pursuant to 52 U.S.C. 30109.
Matters relating to internal personnel
decisions, or internal rules and
practices. Information the premature
disclosure of which would be likely to
have a considerable adverse effect on
the implementation of a proposed
Commission action.
*
*
*
*
*
PERSON TO CONTACT FOR INFORMATION:
Judith Ingram, Press Officer, Telephone:
(202) 694–1220.
AGENCY:

DATE AND TIME:

FEDERAL DEPOSIT INSURANCE
CORPORATION

mstockstill on DSK3G9T082PROD with NOTICES

Sunshine Act Meeting
Pursuant to the provisions of the
‘‘Government in the Sunshine Act’’ (5
U.S.C. 552b), notice is hereby given that
the Federal Deposit Insurance
Corporation’s Board of Directors will
meet in open session at 10:00 a.m. on
Tuesday, March 21, 2017, to consider
the following matters:
Summary Agenda: No substantive
discussion of the following items is
anticipated. These matters will be
resolved with a single vote unless a
member of the Board of Directors
requests that an item be moved to the
discussion agenda.
Disposition of minutes of previous
Board of Directors’ Meetings.
Summary reports, status reports,
reports of actions taken pursuant to
authority delegated by the Board of
Directors, and reports of the Office of
Inspector General.
Discussion Agenda: Update of
Projected Deposit Insurance Fund
Losses, Income, and Reserve Ratios for
the Restoration Plan.
The meeting will be held in the Board
Room located on the sixth floor of the
FDIC Building located at 550 17th Street
NW., Washington, DC.
This Board meeting will be Webcast
live via the Internet and subsequently
made available on-demand
approximately one week after the event.
Visit http://fdic.windrosemedia.com to
view the event. If you need any
technical assistance, please visit our
Video Help page at: https://
www.fdic.gov/video.html.
The FDIC will provide attendees with
auxiliary aids (e.g., sign language
interpretation) required for this meeting.
Those attendees needing such assistance
should call 703–562–2404 (Voice) or
703–649–4354 (Video Phone) to make
necessary arrangements.
Requests for further information
concerning the meeting may be directed

VerDate Sep<11>2014

17:12 Mar 15, 2017

Jkt 241001

Dayna C. Brown,
Secretary and Clerk of the Commission.
[FR Doc. 2017–05397 Filed 3–14–17; 4:15 pm]

available for inspection at the offices of
the Board of Governors. Interested
persons may express their views in
writing on the standards enumerated in
the BHC Act (12 U.S.C. 1842(c)). If the
proposal also involves the acquisition of
a nonbanking company, the review also
includes whether the acquisition of the
nonbanking company complies with the
standards in section 4 of the BHC Act
(12 U.S.C. 1843). Unless otherwise
noted, nonbanking activities will be
conducted throughout the United States.
Unless otherwise noted, comments
regarding each of these applications
must be received at the Reserve Bank
indicated or the offices of the Board of
Governors not later than April 10, 2017.
A. Federal Reserve Bank of Kansas
City (Dennis Denney, Assistant Vice
President) 1 Memorial Drive, Kansas
City, Missouri 64198–0001:
1. Bern Bancshares, Inc., Bern,
Kansas; to acquire up to 6.36 percent of
the voting shares of UBT Bancshares,
Inc., Marysville, Kansas, and thereby
indirectly acquire United Bank & Trust,
Marysville, Kansas.
Board of Governors of the Federal Reserve
System, March 13, 2017.
Yao-Chin Chao,
Assistant Secretary of the Board.
[FR Doc. 2017–05241 Filed 3–15–17; 8:45 am]
BILLING CODE 6210–01–P

DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention

BILLING CODE 6715–01–P

[60Day–17–17SG; Docket No. CDC–2017–
0016]

FEDERAL RESERVE SYSTEM

Proposed Data Collection Submitted
for Public Comment and
Recommendations

Formations of, Acquisitions by, and
Mergers of Bank Holding Companies
The companies listed in this notice
have applied to the Board for approval,
pursuant to the Bank Holding Company
Act of 1956 (12 U.S.C. 1841 et seq.)
(BHC Act), Regulation Y (12 CFR part
225), and all other applicable statutes
and regulations to become a bank
holding company and/or to acquire the
assets or the ownership of, control of, or
the power to vote shares of a bank or
bank holding company and all of the
banks and nonbanking companies
owned by the bank holding company,
including the companies listed below.
The applications listed below, as well
as other related filings required by the
Board, are available for immediate
inspection at the Federal Reserve Bank
indicated. The applications will also be

PO 00000

Frm 00028

Fmt 4703

Sfmt 4703

Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice with comment period.
AGENCY:

The Centers for Disease
Control and Prevention (CDC), as part of
its continuing efforts to reduce public
burden and maximize the utility of
government information, invites the
general public and other Federal
agencies to take this opportunity to
comment on proposed and/or
continuing information collections, as
required by the Paperwork Reduction
Act of 1995. This notice invites
comment on the proposed information
collection project titled
‘‘Anthropometric Information on Law
Enforcement Officers.’’ The purpose of

SUMMARY:

E:\FR\FM\16MRN1.SGM

16MRN1

mstockstill on DSK3G9T082PROD with NOTICES

Federal Register / Vol. 82, No. 50 / Thursday, March 16, 2017 / Notices
this three-year data collection project is
to assemble a database of body
dimensions of 1,000 law enforcement
officers to improve the design of police
cruiser cabins and personal protective
equipment (PPE).
DATES: Written comments must be
received on or before May 15, 2017.
ADDRESSES: You may submit comments,
identified by Docket No. CDC–2017–
0016 by any of the following methods:
• Federal eRulemaking Portal:
Regulations.gov. Follow the instructions
for submitting comments.
• Mail: Leroy A. Richardson,
Information Collection Review Office,
Centers for Disease Control and
Prevention, 1600 Clifton Road NE., MS–
D74, Atlanta, Georgia 30329.
Instructions: All submissions received
must include the agency name and
Docket Number. All relevant comments
received will be posted without change
to Regulations.gov, including any
personal information provided. For
access to the docket to read background
documents or comments received, go to
Regulations.gov.
Please note: All public comment
should be submitted through the
Federal eRulemaking portal
(Regulations.gov) or by U.S. mail to the
address listed above.
FOR FURTHER INFORMATION CONTACT: To
request more information on the
proposed project or to obtain a copy of
the information collection plan and
instruments, contact the Information
Collection Review Office, Centers for
Disease Control and Prevention, 1600
Clifton Road NE., MS–D74, Atlanta,
Georgia 30329; phone: 404–639–7570;
Email: [email protected].
SUPPLEMENTARY INFORMATION: Under the
Paperwork Reduction Act of 1995 (PRA)
(44 U.S.C. 3501–3520), Federal agencies
must obtain approval from the Office of
Management and Budget (OMB) for each
collection of information they conduct
or sponsor. In addition, the PRA also
requires Federal agencies to provide a
60-day notice in the Federal Register
concerning each proposed collection of
information, including each new
proposed collection, each proposed
extension of existing collection of
information, and each reinstatement of
previously approved information
collection before submitting the
collection to OMB for approval. To
comply with this requirement, we are
publishing this notice of a proposed
data collection as described below.
Comments are invited on: (a) Whether
the proposed collection of information
is necessary for the proper performance

VerDate Sep<11>2014

17:12 Mar 15, 2017

Jkt 241001

of the functions of the agency, including
whether the information shall have
practical utility; (b) the accuracy of the
agency’s estimate of the burden of the
proposed collection of information; (c)
ways to enhance the quality, utility, and
clarity of the information to be
collected; (d) ways to minimize the
burden of the collection of information
on respondents, including through the
use of automated collection techniques
or other forms of information
technology; and (e) estimates of capital
or start-up costs and costs of operation,
maintenance, and purchase of services
to provide information. Burden means
the total time, effort, or financial
resources expended by persons to
generate, maintain, retain, disclose or
provide information to or for a Federal
agency. This includes the time needed
to review instructions; to develop,
acquire, install and utilize technology
and systems for the purpose of
collecting, validating and verifying
information, processing and
maintaining information, and disclosing
and providing information; to train
personnel and to be able to respond to
a collection of information, to search
data sources, to complete and review
the collection of information; and to
transmit or otherwise disclose the
information.
Proposed Project
Anthropometric Information on Law
Enforcement Officers—New—National
Institute for Occupational Safety and
Health (NIOSH), Centers for Disease
Control and Prevention (CDC).
Background and Brief Description
The mission of the National Institute
for Occupational Safety and Health
(NIOSH) is to promote safety and health
at work for all people through research
and prevention. The National Bureau of
Standards (NBS) released its manually
measured anthropometric data of law
enforcement officer (LEOs) in 1975. The
data have largely become outdated due
to demographic changes (e.g., gender
and race/ethnicity) that have occurred
in the past 41 years. NIOSH has
initiated a national study on LEO
anthropometry, using both traditional
and three-dimensional (3D) scanning
technologies to advance the safety and
health of approximately 817,000 U.S.
LEOs.
Traditional anthropometry will
ensure easy comparison of data between
this and previous studies, whereas 3D
scan information (body contours and
spatial relations between body parts)
will be used for advanced

PO 00000

Frm 00029

Fmt 4703

Sfmt 4703

14001

anthropometric analysis, computer
simulation, and modeling. Study results
will be used to enhance design and
standards for LEO vehicle configuration
and personal protective equipment
(PPE), such as cabins, seats, body
restraints, vehicle access, and body
armor. Law enforcement officer
anthropometry has an important role in
the design of ergonomically efficient
LEO cruisers and personal protective
systems. The improved vehicle
configurations will help enhance safe
operation (due to improved driver
visibility and control operation) and
increase post-crash survivability (due to
enhanced seats and restraint system
configurations). Body armor, helmet,
gloves, and boots are important
elements of an integrated LEO personal
protective system, especially for
handling violent acts. Poor equipment
fit may compromise protective
capabilities of PPE and may result in
LEOs not wearing the PPE because of
discomfort. By establishing an
anthropometric database for LEOs, the
designers and manufacturers of these
types of equipment will be able to
produce more effective products and
reduce the problems associated with
sizing and stocking these items.
Data collection will occur in four U.S.
geographic areas using traditional
anthropometric techniques for whole
body measurements, 3D scanning
techniques for head, foot, and whole
body measurements, and a twodimensional(2D) scanning techniques
for hand measurements. An
anthropometer, a beam caliper
(rearranged pieces of the
anthropometer), tape measures, and an
electronic scale will be used to collect
the traditional anthropometry data in
the study. A hand scanner, head
scanner, foot scanner, and whole body
scanner, housed in a mobile trailer, are
used for 2D and 3D body shape
measurements.
The study population will be current
law enforcement officers employed by
police departments, sheriff’s
departments, or similar governmental
organizations throughout the
continental United States. One thousand
LEO volunteers will participate in the
study over three years. Informed
consent and the data collection are
expected to take no longer than 65
minutes (total) to complete. The total
estimated annualized burden hours are
385.
There are no costs to the respondents
other than their time.
Estimated Annualized Burden Hours

E:\FR\FM\16MRN1.SGM

16MRN1

14002

Federal Register / Vol. 82, No. 50 / Thursday, March 16, 2017 / Notices

Type of respondents

Law
Law
Law
Law

Enforcement
Enforcement
Enforcement
Enforcement

Officers
Officers
Officers
Officers

................
................
................
................

Average
burden per
response
(in hrs)

Number of
responses per
respondent

Total burden
(in hrs)

333
333
333
333

1
1
1
1

1/60
3/60
5/60
30/60

6
17
28
167

Law Enforcement Officers ................

Pre-Enrollment Confirmation Email ..
Biographical Information ..................
Consent form ....................................
Traditional anthropometric measurements.
2D and 3D scans .............................

333

1

30/60

167

Total ...........................................

...........................................................

........................

........................

........................

385

Leroy A. Richardson,
Chief, Information Collection Review Office,
Office of Scientific Integrity, Office of the
Associate Director for Science, Office of the
Director, Centers for Disease Control and
Prevention.

Dated: March 13, 2017.
Leslie Kux,
Associate Commissioner for Policy.

[FR Doc. 2017–05265 Filed 3–15–17; 8:45 am]

[FR Doc. 2017–05247 Filed 3–15–17; 8:45 am]

BILLING CODE 4163–18–P

BILLING CODE 4164–01–P

DEPARTMENT OF HEALTH AND
HUMAN SERVICES

DEPARTMENT OF HEALTH AND
HUMAN SERVICES

Food and Drug Administration

Food and Drug Administration

[Docket No. FDA–N–2016–4198]

[Docket No. FDA–2016–P–1676]

Public Meeting on Patient-Focused
Drug Development for Sarcopenia;
Request for Comments; Correction

Determination that
CYANOCOBALAMIN INJECTION, 1
Milligram per Milliliter in a 10 Milliliter
Vial, Was Not Withdrawn From Sale for
Reasons of Safety or Effectiveness

AGENCY:

Food and Drug Administration,

HHS.
ACTION:

17:12 Mar 15, 2017

Food and Drug Administration,

HHS.

The Food and Drug
Administration is correcting a notice
entitled ‘‘Public Meeting on PatientFocused Drug Development for
Sarcopenia’’ that appeared in the
Federal Register of December 14, 2016
(81 FR 90361). The document
announced a public meeting and an
opportunity for public comment on
Patient-Focused Drug Development for
Sarcopenia. The location of the meeting
has changed and this document
provides the updated meeting location.
FOR FURTHER INFORMATION CONTACT:
Meghana Chalasani, Center for Drug
Evaluation and Research, Food and
Drug Administration, 10903 New
Hampshire Ave., Bldg. 51, Rm. 1146,
Silver Spring, MD 20993–0002, 240–
402–6525, FAX: 301–847–8443,
[email protected].
In the Federal Register of Wednesday,
December 14, 2016, in FR Doc. 2016–
29998, the following correction is made:
1. On page 90361, in the second
column, in the first sentence of the
ADDRESSES section, ‘‘FDA White Oak
Campus, 10903 New Hampshire Ave.,
Bldg. 31 Conference Center, the Great
Room, (Rm. 1503), Silver Spring, MD
20993–0002.’’ is corrected to read
‘‘Tommy Douglas Conference Center,

VerDate Sep<11>2014

10000 New Hampshire Ave., Silver
Spring, MD 20903.’’

AGENCY:

Notice; correction.

SUMMARY:

mstockstill on DSK3G9T082PROD with NOTICES

Number of
respondents

Form name

Jkt 241001

ACTION:

Notice.

The Food and Drug
Administration (FDA or Agency) has
determined that CYANOCOBALAMIN
INJECTION, 1 milligram per milliliter in
a 10 milliliter vial, was not withdrawn
from sale for reasons of safety or
effectiveness. This determination means
that FDA will not begin procedures to
withdraw approval of abbreviated new
drug applications (ANDAs) that refer to
this drug product, and it will allow FDA
to continue to approve ANDAs that refer
to the product as long as they meet
relevant legal and regulatory
requirements.
FOR FURTHER INFORMATION CONTACT:
Elizabeth Trentacost, Center for Drug
Evaluation and Research, Food and
Drug Administration, 10903 New
Hampshire Ave., Bldg. 51, Rm. 6219,
Silver Spring, MD 20993–0002, 240–
402–7736.
SUPPLEMENTARY INFORMATION: In 1984,
Congress enacted the Drug Price
Competition and Patent Term
Restoration Act of 1984 (Pub. L. 98–417)
(the 1984 amendments), which
authorized the approval of duplicate
versions of drug products under an
ANDA procedure. ANDA applicants
SUMMARY:

PO 00000

Frm 00030

Fmt 4703

Sfmt 4703

must, with certain exceptions, show that
the drug for which they are seeking
approval contains the same active
ingredient in the same strength, dosage
form, and route of administration as the
‘‘listed drug,’’ which is a version of the
drug that was previously approved.
ANDA applicants do not have to repeat
the extensive clinical testing otherwise
necessary to gain approval of a new
drug application (NDA).
The 1984 amendments include what
is now section 505(j)(7) of the Federal
Food, Drug, and Cosmetic Act (21 U.S.C.
355(j)(7)), which requires FDA to
publish a list of all approved drugs.
FDA publishes this list as part of the
‘‘Approved Drug Products With
Therapeutic Equivalence Evaluations,’’
which is known generally as the
‘‘Orange Book.’’ Under FDA regulations,
drugs are removed from the list if the
Agency withdraws or suspends
approval of the drug’s NDA or ANDA
for reasons of safety or effectiveness or
if FDA determines that the listed drug
was withdrawn from sale for reasons of
safety or effectiveness (21 CFR 314.162).
A person may petition the Agency to
determine, or the Agency may
determine on its own initiative, whether
a listed drug was withdrawn from sale
for reasons of safety or effectiveness.
This determination may be made at any
time after the drug has been withdrawn
from sale, but must be made prior to
approving an ANDA that refers to the
listed drug (21 CFR 314.161). FDA may
not approve an ANDA that does not
refer to a listed drug.
CYANOCOBALAMIN INJECTION, 1
milligram per milliliter in a 10 milliliter
vial, is the subject of ANDA 080557,
held by Fresenius Kabi USA (Fresenius),
and initially approved on June 20, 1973.
CYANOCOBALAMIN INJECTION is
indicated for vitamin B12 deficiencies
due to malabsorption that may be
associated with the following
conditions: Addisonian (pernicious)
anemia; gastrointestinal pathology,
dysfunction, or surgery, including
gluten enteropathy or sprue, small
bowel bacterial overgrowth, and total or
partial gastrectomy; fish tapeworm

E:\FR\FM\16MRN1.SGM

16MRN1